SAB Common Stock Shares Outstanding from 2010 to 2024

SABSW Stock  USD 0.07  0  5.75%   
SAB Biotherapeutics Common Stock Shares Outstanding yearly trend continues to be fairly stable with very little volatility. Common Stock Shares Outstanding is likely to outpace its year average in 2024. Common Stock Shares Outstanding is the total number of shares of a company's common stock that are currently owned by all its shareholders. View All Fundamentals
 
Common Stock Shares Outstanding  
First Reported
2010-12-31
Previous Quarter
5.5 M
Current Value
9.4 M
Quarterly Volatility
18.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Interest Income of 80.1 K, Depreciation And Amortization of 3.9 M or Interest Expense of 289.4 K, as well as many indicators such as Price To Sales Ratio of 16.12, Dividend Yield of 0.0 or PTB Ratio of 0.7. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of SAB Biotherapeutics Correlation against competitors.
For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

Latest SAB Biotherapeutics' Common Stock Shares Outstanding Growth Pattern

Below is the plot of the Common Stock Shares Outstanding of SAB Biotherapeutics over the last few years. It is the total number of shares of a company's common stock that are currently owned by all its shareholders. SAB Biotherapeutics' Common Stock Shares Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SAB Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Common Stock Shares Outstanding10 Years Trend
Slightly volatile
   Common Stock Shares Outstanding   
       Timeline  

SAB Common Stock Shares Outstanding Regression Statistics

Arithmetic Mean30,630,817
Geometric Mean20,276,454
Coefficient Of Variation61.57
Mean Deviation17,125,283
Median43,474,779
Standard Deviation18,859,487
Sample Variance355.7T
Range40.8M
R-Value(0.80)
Mean Square Error136.6T
R-Squared0.64
Significance0.0003
Slope(3,382,504)
Total Sum of Squares4979.5T

SAB Common Stock Shares Outstanding History

20249.4 M
20235.5 M
20224.4 M
20212.7 M
20202.7 M

About SAB Biotherapeutics Financial Statements

SAB Biotherapeutics investors use historical fundamental indicators, such as SAB Biotherapeutics' Common Stock Shares Outstanding, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in SAB Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Common Stock Shares Outstanding5.5 M9.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.